MINPP1 and isolated focal cortical dysplasia type II: Given the exacerbated inflammation induced by Cdt and Aa infection in MIPP, LGM2605 emerges as a promising therapeutic agent to counteract the detrimental effects observed, aligning with its success in managing similar pathological conditions.